1832 Asset Management
HTGM

1832 Asset Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

1832 Asset Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6
Closed – – 941
2022
Q2 		$0 Hold
6
– – ﹤0.01% 995
2022
Q1 		$0 Buy
+6
New +$193 ﹤0.01% 1005

Other funds holding HTGM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

1832 Asset Management's HTGM Position: Q3 2022 in Review

1832 Asset Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q3 2022, closing a stake of 6 shares.

1832 Asset Management first reported a position in HTGM in Q1 2022 and held it in 2 quarters. The position peaked at $0 in Q2 2022. 18 funds tracked by Wall St. Rank hold HTGM as of Q3 2022.

  • 1832 Asset Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • 1832 Asset Management sold 6 HTG Molecular Diagnostics, Inc. Common Stock shares in Q3 2022.
  • 1832 Asset Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q1 2022 and held it in 2 quarters.
  • 1832 Asset Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $0 in Q2 2022.
  • 18 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q3 2022.

Based on 1832 Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.